> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# AMA Delegates Call for Tighter FDA Oversight of Unapproved Peptides
- URL: https://www.fdaweb.com/ama-delegates-call-for-tighter-fda-oversight-of-unapproved-peptides/
- Published: 2026-06-09T12:00:00.000Z
- Updated: 2026-09-14T13:40:46.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5161282

Delegates at the American Medical Association's (AMA) annual meeting have voted to support stronger FDA oversight of synthetic peptide products, citing growing concerns about the widespread use of unapproved compounds marketed for weight loss, wound healing, longevity, and other health claims without robust clinical evidence. Peptides — short chains of amino acids designed to influence biological processes — have surged in popularity in recent years, particularly among fitness and longevity communities.

The AMA House of Delegates adopted a resolution urging FDA to require unapproved synthetic peptides to undergo regulatory review, third-party testing, and demonstration of safety and efficacy through well-controlled clinical trials before they are marketed, compounded, or used clinically.

The action comes as consumer interest in peptides has surged, fueled in part by wellness influencers and podcasts promoting compounds for indications ranging from tissue repair to anti-aging. It reflects a broader policy discussion underway in Washington over the regulation of peptides and compounded products. HHS secretary **Robert F. Kennedy Jr.** has criticized existing restrictions on peptide compounding, arguing that they may contribute to an illicit market for such products. FDA officials have also recently met with dietary supplement manufacturers interested in incorporating peptide ingredients into consumer products.

Meanwhile, FDA's Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet 7/23-24 to discuss several synthetic peptides and review evidence related to their proposed uses across a range of conditions, including ulcerative colitis, wound healing, inflammatory disorders, osteoporosis, opioid withdrawal, insomnia, narcolepsy, migraine, cerebral ischemia, and trigeminal neuralgia. The [meeting](https://public-inspection.federalregister.gov/2026-07361.pdf?ref=fdaweb.com) is presumably part of HHS’ move to reverse a 2023 FDA decision that deemed a group of peptide drugs too risky for use by compounding pharmacies.

Kennedy has criticized FDA’s earlier action as “illegal,” arguing the agency overstepped its authority by evaluating the effectiveness of the substances rather than focusing solely on safety, [according to *ProPublica*](https://www.propublica.org/article/peptide-safety-fda-compounding-pharmacies?ref=fdaweb.com). Speaking on *The Joe Rogan Experience*, Kennedy recently said regulators lacked sufficient evidence of harm to justify restricting the peptides.

However, several former FDA officials dispute that claim, saying the agency’s decision was grounded in documented safety risks and consistent with longstanding regulatory standards requiring evaluation of both safety and efficacy. Among them, former acting FDA commissioner **Janet Woodcock** warned that reversing the policy could undermine decades of drug oversight, *ProPublica* reports. “It would be a disruption of the societal pact we have had since 1962 that drugs will be studied to see if they work before they are marketed in the U.S.,” Woodcock said